A comparative study of chitosan and poloxamer based thermosensitive hydrogel for the delivery of PEGylated melphalan conjugates

Drug Development and Industrial Pharmacy

Volumn 41, Issue 12, 2015, Pages 1954-1961

  Alexander, Amit ^a   Saraf, Swarnlata ^a   Saraf, Shailendra ^a  

^a PT RAVISHANKAR SHUKLA UNIVERSITY   (India)

Author keywords

Anti cancer; Chitosan; Hydrogel; MCF; Melphalan; MTT; PEGylation; Poloxamer

Indexed keywords

CHITOSAN; DRUG CARRIER; MELPHALAN; POLOXAMER; HYDROGEL; MACROGOL DERIVATIVE;

ARTICLE; CELL VIABILITY; COMPARATIVE STUDY; CONJUGATION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HEMOLYSIS; HYDROGEL; HYDROLYSIS; IN VITRO STUDY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SUSTAINED DRUG RELEASE; THERMOSENSITIVE HYDROGEL; VALIDATION PROCESS; ADMINISTRATION AND DOSAGE; BLOOD; CHEMISTRY; DOSE RESPONSE; HUMAN; METABOLISM; PROCEDURES; TEMPERATURE;

CHITOSAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGELS; MELPHALAN; POLOXAMER; POLYETHYLENE GLYCOLS; TEMPERATURE;

EID: 84930941896     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2015.1011167     Document Type: Article

References (51)

1. Farmer PB. Metabolism and reactions of alkylating agents. Pharmacol Ther 1987;35:301-58.
2. Rothbarth J, Koevoets C, Tollenaar RA, et al. Immunohistochemical detection of melphalan-DNA adducts in colon cancer cells in vitro and human colorectal liver tumours in vivo. Biochem Pharmacol 2004;67:1771-8.
3. Cozzi P. The discovery of a new potential anticancer drug: a case history. Il Farmaco 2003;58:213-20.
4. Denny WA. DNA minor groove alkylating agents. Curr Med Chem 2001;8:533-44.
5. Bartulewicz D, Bielawski K, Bielawska A, Rozanski A. Synthesis, molecular modelling, and antiproliferative and cytotoxic effects of carbocyclic derivatives of distamycin with chlorambucil moiety. Eur J Med Chem 2001;36:461-7.
6. Haddow A, Timmis GM. Myleran in chronic myeloid leukaemia; chemical constitution and biological action. Lancet 1953;264:207-8.
7. Knock FE. Newer anticancer agents. Med Clin N Am 1964;48:501-27.
8. Hanada K, Budzowska M, Modesti M, et al. The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks. EMBO J 2006;25:4921-32.
9. Valdez BC, Nieto Y, Murray D, et al. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol 2012;40:800-10.
10. Brookes P, Lawley PD. Reaction of some mutagenic and carcinogenic compounds with nucleic acids. J Cell Comp Physiol 1964;64:111-28.
11. Li S, Wang X, He Y, et al. Design and synthesis of novel quinazoline nitrogen mustard derivatives as potential therapeutic agents for cancer. Eur J Med Chem 2013;67:293-301.
12. Arias JL, López-Viota M, Gallardo V, Ruiz MA. Chitosan nanoparticles as a new delivery system for the chemotherapy agent tegafur. Drug Dev Ind Pharm 2010;36:744-50.
13. Nagamine MK, Da Silva TC, Matsuzaki P, et al. Cytotoxic effects of butanolic extract from Pfaffia paniculata (Brazilian ginseng) on cultured human breast cancer cell line MCF-7. Exp Toxicol Pathol 2009;61:75-82.
14. Valizadeh H, Ghanbarzadeh S, Zakeri-Milani P. Fusogenic liposomal formulation of sirolimus: improvement of drug anti-proliferative effect on human T-cells. Drug Dev Ind Pharm 2014. [Epub ahead of print]. doi:10.3109/03639045.2014.971032.
15. Soule HD, Vazguez J, Long A, et al. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973;51:1409-16.
16. Natarajan N, Thamaraiselvan R, Lingaiah H, et al. Effect of flavonone hesperidin on the apoptosis of human mammary carcinoma cell line MCF-7. Biomed Prev Nutr 2011;1:207-15.
17. Hennink WE, Van Nostrum CF. Novel crosslinking methods to design hydrogels. Adv Drug Deliv Rev 2012;64:223-36.
18. Sallam MA, Motawaa AM, Mortada SM. An insight on human skin penetration of diflunisal: lipogel versus hydrogel microemulsion. Drug Dev Ind Pharm 2015;41:141-7.
19. Lee KY, Mooney DJ. Hydrogels for tissue engineering. Chem Rev 2001;101:1869-79.
20. Kopecek J. Hydrogels from soft contact lenses and implants to self-assembled nanomaterials. J Polym Sci Part A, Polym Chem 2009;47:5929-46.
21. Itoh K, Kubo W, Fujiwara M, et al. The influence of variation of gastric pH on the gelation and release characteristics of in situ gelling pectin formulations. Int J Pharm 2006;312:37-42.
22. Shim WS, Kim J-H, Kim K, et al. pH- and temperature-sensitive, injectable, biodegradable block copolymer hydrogels as carriers for paclitaxel. Int J Pharm 2007;331:11-18.
23. Ko DY, Shinde UP, Yeon B, Jeong B. Recent progress of in situ formed gels for biomedical applications. Prog Polym Sci 2013;38:672-701.
24. Mohd Amin MCI, Ahmad N, Pandey M, Jue Xin C. Stimuliresponsive bacterial cellulose-g-poly (acrylic acid-co-acrylamide) hydrogels for oral controlled release drug delivery. Drug Dev Ind Pharm 2014;40:1340-9.
25. Xu Y, Shen Y, Xiong Y, et al. Synthesis, characterization, biodegradability and biocompatibility of a temperature-sensitive PBLA-PEG-PBLA hydrogel as protein delivery system with low critical gelation concentration. Drug Dev Ind Pharm 2014;40:1264-75.
26. Hoffman AS. Applications of thermally reversible polymers and hydrogels in therapeutics and diagnostics. J Control Release 1987;6:297-305.
27. Peppas NA, Klier J. Controlled release by using poly (methacrylic acid-g-ethylene glycol) hydrogels. J Control Release 1991;16:203-14.
28. Chen G, Hoffman AS. Graft copolymers that exhibit temperatureinduced phase transitions over a wide range of pH. Nature 1995;373:49-52.
29. Ajazuddin, Alexander A, Khan J, et al. Advancement in stimuli triggered in situ gelling delivery for local and systemic route. Expert Opin Drug Deliv 2012;9:1573-92.
30. Liu Z, Calvert P. Multilayer hydrogels as muscle-like actuators. Adv Mater 2000;12:288-91.
31. Kim SJ, Yoon SG, Lee YM, Kim SI. Electrical sensitive behavior of poly (vinyl alcohol)/poly (diallyldimethylammonium chloride) IPN hydrogel. Sensor Actuat B: Chem 2003;88:286-91.
32. Bromberg LE, Ron ES. Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery. Adv Drug Deliv Rev 1998;31:197-221.
33. Alexander A, Ajazuddin, Khan J, et al. Polyethylene glycol (PEG) - poly (N-isopropylacrylamide) (PNIPAAm) based thermosensitive injectable hydrogels for biomedical applications. Eur J Pharm Biopharm 2014;88:575-85.
34. Alexander A, Ajazuddin, Khan J, et al. Poly (ethylene glycol) - poly (lactic-co-glycolic acid) based thermosensitive injectable hydrogels for biomedical applications. J Control Release 2013;172:715-29.
35. Singla AK, Chawla M. Chitosan: some pharmaceutical and biological aspects - an update. J Pharm Pharmacol 2001;53:1047-67.
36. Hasanovic A, Zehl M, Reznicek G, Valenta C. Chitosan-tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability. J Pharm Pharmacol 2009;61:1609-16.
37. Uchegbu IF, Schätzlein AG, Tetley L, et al. Polymeric chitosanbased vesicles for drug delivery. J Pharm Pharmacol 1998;50:453-8.
38. Çelebi N, Ermiş S, Özkan S. Development of topical hydrogels of terbinafine hydrochloride and evaluation of their antifungal activity. Drug Dev Ind Pharm 2014. [Epub ahead of print]. doi:10.3109/03639045.2014.891129.
39. Tan ML, Choong PFM, Dass CR. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol 2009;61:3-12.
40. Albasarah YY, Somavarapu S, Stapleton P, Taylor KM. Chitosancoated antifungal formulations for nebulisation. J Pharm Pharmacol 2010;62:821-8.
41. Chenite A, Chaput C, Wang D, et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials 2000;21:2155-61.
42. Xuan J-J, Balakrishnan P, Oh DH, et al. Rheological characterization and in vivo evaluation of thermosensitive poloxamer-based hydrogel for intramuscular injection of piroxicam. Int J Pharm 2010;395:317-23.
43. Chen X, Zhi F, Jia X, et al. Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel. J Pharm Pharmacol 2013;65:807-16.
44. Al-Saden A, Florence AT, Whateley TL. Novel poloxamer (pluronic) and poloxamine (tetronic) hydrogels: swelling and drug release. J Pharm Pharmacol 1980;32:5P.
45. Ajazuddin, Alexander A, Amarji B, Kanaujia P. Synthesis, characterization and in vitro studies of pegylated melphalan conjugates. Drug Dev Ind Pharm 2013;39:1053-62.
46. Alexander A, Ajazuddin, Khan J, et al. Formulation and evaluation of chitosan-based long-acting injectable hydrogel for PEGylated melphalan conjugate. J Pharm Pharmacol 2014;66:1240-50.
47. Schmolka IR. Artificial skin I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res 1972;6:571-82.
48. Cardile V, Renis M, Scifo C, et al. Behaviour of the new asbestos amphibole fluoro-edenite in different lung cell systems. Int J Biochem Cell Biol 2004;36:849-60.
49. Ta HT, Dass CR, Larson I, et al. A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma. Biomaterials 2009;30:3605-13.
50. Nasir F, Iqbal Z, Khan A, et al. Development and evaluation of pluronic- and methylcellulose-based thermoreversible drug delivery system for insulin. Drug Dev Ind Pharm 2014;40:1503-8.
51. Gao M, Xu H, Zhang C, et al. Preparation and characterization of curcumin thermosensitive hydrogels for intratumoral injection treatment. Drug Dev Ind Pharm 2014;40:1557-64.